Quality of life valuations of mammography screening
Quality of life valuations of mammography screening
复制标题
DOI：
10.1007/s11136-008-9353-2
复制
发表时间：
2008-06-01
影响因子：
3.5
通讯作者：
Seger, Deb
中科院分区：
文献类型：
--
作者：
Bonomi, Amy E.;Boudreau, Denise M.;Seger, Deb
目的获得生活质量（QOL）的评价与乳腺X线摄影筛查和乳腺癌治疗是适合使用的成本效益analysis.Methods包括131名妇女（年龄范围50-79岁）随机抽样的乳腺癌筛查计划。在面对面或电话采访中，女性对14种临床情况的生活质量影响进行了评估（范围从乳房X光检查到乳腺癌的临终护理）使用以死亡（0）和完美健康/生活质量（100）为锚定的视觉模拟量表。而常规筛查乳房X光检查在0-100分的范围内为80分或以上，这表明他们认为这些状态接近完美健康。他们将辅助化疗（39.7;范围10-90），姑息/临终关怀（35.8;范围0-100）和1年复发（33.0;范围0-95）评为最低，表明这些健康状态被认为是受损的。接受乳腺癌诊断消息的女性（真阳性）（45.7;范围5-100）和延迟收到乳腺癌诊断的消息（假阴性）（48.5;范围5-100）与接受乳房切除术相当结论这些数据可用于更新乳腺X线检查筛查的成本分析，希望考虑到筛查对生活质量的影响。
Objective To obtain quality-of-life (QOL) valuations associated with mammography screening and breast cancer treatment that are suitable for use in cost-effectiveness analyses.Methods Subjects comprised 131 women (age range 50-79 years) randomly sampled from a breast cancer screening program. In an in-person or telephone interview, women rated the QOL impact of 14 clinical scenarios (ranging from mammography to end-of-life care for breast cancer) using a visual analogue scale anchored by death (0) and perfect health/quality of life (100).Results Women rated the scenarios describing true negative results, false positive results, and routine screening mammography at 80 or above on a scale of 0-100, suggesting that they perceive these states as being close to perfect health. They rated adjuvant chemotherapy (39.7; range 10-90), palliation/end-of-life care (35.8; range 0-100), and recurrence at 1 year (33.0; range 0-95) the lowest, suggesting that these health states are perceived as compromised. Women rated receiving news of a breast cancer diagnosis (true positive) (45.7; range 5-100) and receiving delayed news of a breast cancer diagnosis (false negative) (48.5; range 5-100) as being comparable to undergoing mastectomy (48.3; range 10-100) and radiation therapy (46.2; range 5-100) for breast cancer.Conclusions These data can be used to update cost analyses of mammography screening that wish to take into account the QOL impact of screening.